Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Jul;111(9):1202–1208. doi: 10.1289/ehp.5999

Skin as a route of exposure and sensitization in chronic beryllium disease.

Sally S Tinkle 1, James M Antonini 1, Brenda A Rich 1, Jenny R Roberts 1, Rebecca Salmen 1, Karyn DePree 1, Eric J Adkins 1
PMCID: PMC1241575  PMID: 12842774

Abstract

Chronic beryllium disease is an occupational lung disease that begins as a cell-mediated immune response to beryllium. Although respiratory and engineering controls have significantly decreased occupational beryllium exposures over the last decade, the rate of beryllium sensitization has not declined. We hypothesized that skin exposure to beryllium particles would provide an alternative route for sensitization to this metal. We employed optical scanning laser confocal microscopy and size-selected fluorospheres to demonstrate that 0.5- and 1.0- micro m particles, in conjunction with motion, as at the wrist, penetrate the stratum corneum of human skin and reach the epidermis and, occasionally, the dermis. The cutaneous immune response to chemical sensitizers is initiated in the skin, matures in the local lymph node (LN), and releases hapten-specific T cells into the peripheral blood. Topical application of beryllium to C3H mice generated beryllium-specific sensitization that was documented by peripheral blood and LN beryllium lymphocyte proliferation tests (BeLPT) and by changes in LN T-cell activation markers, increased expression of CD44, and decreased CD62L. In a sensitization-challenge treatment paradigm, epicutaneous beryllium increased murine ear thickness following chemical challenge. These data are consistent with development of a hapten-specific, cell-mediated immune response following topical application of beryllium and suggest a mechanistic link between the persistent rate of beryllium worker sensitization and skin exposure to fine and ultrafine beryllium particles.

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alekseeva O. G. Izuchenie sposobnosti soedinenii berilliia vyzyvat' allergiiu zamedlennogo tipa. Gig Tr Prof Zabol. 1965 Nov;9(11):20–25. [PubMed] [Google Scholar]
  2. Andersson K. G., Fogh C. L., Byrne M. A., Roed J., Goddard A. J. H., Hotchkiss S. A. M. Radiation dose implications of airborne contaminant deposition to humans. Health Phys. 2002 Feb;82(2):226–232. doi: 10.1097/00004032-200202000-00007. [DOI] [PubMed] [Google Scholar]
  3. Belman S. Beryllium binding of epidermal constituents. J Occup Med. 1969 Apr;11(4):175–183. doi: 10.1097/00043764-196904000-00003. [DOI] [PubMed] [Google Scholar]
  4. Blundell G., Henderson W. J., Price E. W. Soil particles in the tissues of the foot in endemic elephantiasis of the lower legs. Ann Trop Med Parasitol. 1989 Aug;83(4):381–385. doi: 10.1080/00034983.1989.11812361. [DOI] [PubMed] [Google Scholar]
  5. Bobka C. A., Stewart L. A., Engelken G. J., Golitz L. E., Newman L. S. Comparison of in vivo and in vitro measures of beryllium sensitization. J Occup Environ Med. 1997 Jun;39(6):540–547. doi: 10.1097/00043764-199706000-00009. [DOI] [PubMed] [Google Scholar]
  6. CURTIS G. H. Cutaneous hypersensitivity due to beryllium; a study of thirteen cases. AMA Arch Derm Syphilol. 1951 Oct;64(4):470–482. doi: 10.1001/archderm.1951.01570100087014. [DOI] [PubMed] [Google Scholar]
  7. Corachan M., Tura J. M., Campo E., Soley M., Traveria A. Podoconiosis in Aequatorial Guinea. Report of two cases from different geological environments. Trop Geogr Med. 1988 Oct;40(4):359–364. [PubMed] [Google Scholar]
  8. Denham S., Hall J. G. Studies on the adjuvant action of beryllium. III. The activity in the plasma of lymph efferent from nodes stimulated with beryllium. Immunology. 1988 Jun;64(2):341–344. [PMC free article] [PubMed] [Google Scholar]
  9. Dreher F., Arens A., Hostýnek J. J., Mudumba S., Ademola J., Maibach H. I. Colorimetric method for quantifying human Stratum corneum removed by adhesive-tape stripping. Acta Derm Venereol. 1998 May;78(3):186–189. doi: 10.1080/000155598441495. [DOI] [PubMed] [Google Scholar]
  10. Eisenbud M. Origins of the standards for control of beryllium disease (1947-1949). Environ Res. 1982 Feb;27(1):79–88. doi: 10.1016/0013-9351(82)90059-7. [DOI] [PubMed] [Google Scholar]
  11. Epstein P. E., Dauber J. H., Rossman M. D., Daniele R. P. Bronchoalveolar lavage in a patient with chronic berylliosis: evidence for hypersensitivity pneumonitis. Ann Intern Med. 1982 Aug;97(2):213–216. doi: 10.7326/0003-4819-97-2-213. [DOI] [PubMed] [Google Scholar]
  12. Finch G. L., Nikula K. J., Hoover M. D. Dose-response relationships between inhaled beryllium metal and lung toxicity in C3H mice. Toxicol Sci. 1998 Mar;42(1):36–48. doi: 10.1006/toxs.1997.2412. [DOI] [PubMed] [Google Scholar]
  13. Fontenot Andrew P., Maier Lisa A., Canavera Scott J., Hendry-Hofer Tara B., Boguniewicz Mark, Barker Elizabeth A., Newman Lee S., Kotzin Brian L. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol. 2002 Apr 1;168(7):3627–3634. doi: 10.4049/jimmunol.168.7.3627. [DOI] [PubMed] [Google Scholar]
  14. Henneberger P. K., Cumro D., Deubner D. D., Kent M. S., McCawley M., Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health. 2001 Apr;74(3):167–176. doi: 10.1007/s004200100237. [DOI] [PubMed] [Google Scholar]
  15. Huang H., Meyer K. C., Kubai L., Auerbach R. An immune model of beryllium-induced pulmonary granulomata in mice. Histopathology, immune reactivity, and flow-cytometric analysis of bronchoalveolar lavage-derived cells. Lab Invest. 1992 Jul;67(1):138–146. [PubMed] [Google Scholar]
  16. Jones J. M., Amos H. E. Contact sensitivity in vitro: activation of actively allergized lymphocytes by a beryllium complex. Int Arch Allergy Appl Immunol. 1974;46(2):161–171. doi: 10.1159/000231120. [DOI] [PubMed] [Google Scholar]
  17. Kimber I., Dearman R. J. Investigation of lymph node cell proliferation as a possible immunological correlate of contact sensitizing potential. Food Chem Toxicol. 1991 Feb;29(2):125–129. doi: 10.1016/0278-6915(91)90167-6. [DOI] [PubMed] [Google Scholar]
  18. Kreiss K., Mroz M. M., Newman L. S., Martyny J., Zhen B. Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m3. Am J Ind Med. 1996 Jul;30(1):16–25. doi: 10.1002/(SICI)1097-0274(199607)30:1<16::AID-AJIM3>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  19. Kreiss K., Mroz M. M., Zhen B., Martyny J. W., Newman L. S. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):985–991. doi: 10.1164/ajrccm/148.4_Pt_1.985. [DOI] [PubMed] [Google Scholar]
  20. Kreiss K., Mroz M. M., Zhen B., Wiedemann H., Barna B. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med. 1997 Aug;54(8):605–612. doi: 10.1136/oem.54.8.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kreiss K., Wasserman S., Mroz M. M., Newman L. S. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med. 1993 Mar;35(3):267–274. [PubMed] [Google Scholar]
  22. Krivanek N., Reeves A. L. The effect of chemical forms of beryllium on the production of the immunologic response. Am Ind Hyg Assoc J. 1972 Jan;33(1):45–52. doi: 10.1080/0002889728506606. [DOI] [PubMed] [Google Scholar]
  23. Lademann J., Otberg N., Richter H., Weigmann H. J., Lindemann U., Schaefer H., Sterry W. Investigation of follicular penetration of topically applied substances. Skin Pharmacol Appl Skin Physiol. 2001;14 (Suppl 1):17–22. doi: 10.1159/000056385. [DOI] [PubMed] [Google Scholar]
  24. Lademann J., Weigmann H., Rickmeyer C., Barthelmes H., Schaefer H., Mueller G., Sterry W. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol. 1999 Sep-Oct;12(5):247–256. doi: 10.1159/000066249. [DOI] [PubMed] [Google Scholar]
  25. Martyny J. W., Hoover M. D., Mroz M. M., Ellis K., Maier L. A., Sheff K. L., Newman L. S. Aerosols generated during beryllium machining. J Occup Environ Med. 2000 Jan;42(1):8–18. doi: 10.1097/00043764-200001000-00006. [DOI] [PubMed] [Google Scholar]
  26. McCawley M. A., Kent M. S., Berakis M. T. Ultrafine beryllium number concentration as a possible metric for chronic beryllium disease risk. Appl Occup Environ Hyg. 2001 May;16(5):631–638. doi: 10.1080/10473220120812. [DOI] [PubMed] [Google Scholar]
  27. Menon G. K., Elias P. M. Morphologic basis for a pore-pathway in mammalian stratum corneum. Skin Pharmacol. 1997;10(5-6):235–246. doi: 10.1159/000211511. [DOI] [PubMed] [Google Scholar]
  28. Newman J. L., Seitz J. C. Intermittent use of an antimicrobial hand gel for reducing soap-induced irritation of health care personnel. Am J Infect Control. 1990 Jun;18(3):194–200. doi: 10.1016/0196-6553(90)90184-t. [DOI] [PubMed] [Google Scholar]
  29. Newman L. S., Kreiss K., King T. E., Jr, Seay S., Campbell P. A. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis. 1989 Jun;139(6):1479–1486. doi: 10.1164/ajrccm/139.6.1479. [DOI] [PubMed] [Google Scholar]
  30. Newman L. S., Mroz M. M., Maier L. A., Daniloff E. M., Balkissoon R. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med. 2001 Mar;43(3):231–237. doi: 10.1097/00043764-200103000-00011. [DOI] [PubMed] [Google Scholar]
  31. Okah F. A., Wickett R. R., Pickens W. L., Hoath S. B. Surface electrical capacitance as a noninvasive bedside measure of epidermal barrier maturation in the newborn infant. Pediatrics. 1995 Oct;96(4 Pt 1):688–692. [PubMed] [Google Scholar]
  32. Reeves A. L., Krivanek N. D. The influence of cutaneous hypersensitivity to beryllium on the development of experimental pulmonary berylliosis. Trans N Y Acad Sci. 1974 Jan;36(1):78–93. doi: 10.1111/j.2164-0947.1974.tb01556.x. [DOI] [PubMed] [Google Scholar]
  33. Reis e Sousa C., Stahl P. D., Austyn J. M. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med. 1993 Aug 1;178(2):509–519. doi: 10.1084/jem.178.2.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Richeldi L., Sorrentino R., Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993 Oct 8;262(5131):242–244. doi: 10.1126/science.8105536. [DOI] [PubMed] [Google Scholar]
  35. Rossman M. D., Kern J. A., Elias J. A., Cullen M. R., Epstein P. E., Preuss O. P., Markham T. N., Daniele R. P. Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann Intern Med. 1988 May;108(5):687–693. doi: 10.7326/0003-4819-108-5-687. [DOI] [PubMed] [Google Scholar]
  36. Saltini C., Winestock K., Kirby M., Pinkston P., Crystal R. G. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989 Apr 27;320(17):1103–1109. doi: 10.1056/NEJM198904273201702. [DOI] [PubMed] [Google Scholar]
  37. Tan M. H., Commens C. A., Burnett L., Snitch P. J. A pilot study on the percutaneous absorption of microfine titanium dioxide from sunscreens. Australas J Dermatol. 1996 Nov;37(4):185–187. doi: 10.1111/j.1440-0960.1996.tb01050.x. [DOI] [PubMed] [Google Scholar]
  38. Wang Z., Farris G. M., Newman L. S., Shou Y., Maier L. A., Smith H. N., Marrone B. L. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology. 2001 Aug 13;165(1):27–38. doi: 10.1016/s0300-483x(01)00410-3. [DOI] [PubMed] [Google Scholar]
  39. Wang Z., White P. S., Petrovic M., Tatum O. L., Newman L. S., Maier L. A., Marrone B. L. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999 Aug 1;163(3):1647–1653. [PubMed] [Google Scholar]
  40. Wester R. C., Christoffel J., Hartway T., Poblete N., Maibach H. I., Forsell J. Human cadaver skin viability for in vitro percutaneous absorption: storage and detrimental effects of heat-separation and freezing. Pharm Res. 1998 Jan;15(1):82–84. doi: 10.1023/a:1011904921318. [DOI] [PubMed] [Google Scholar]
  41. van der Molen R. G., Spies F., van 't Noordende J. M., Boelsma E., Mommaas A. M., Koerten H. K. Tape stripping of human stratum corneum yields cell layers that originate from various depths because of furrows in the skin. Arch Dermatol Res. 1997 Aug;289(9):514–518. doi: 10.1007/s004030050232. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES